Neonatal Abstinence Syndrome (NAS) Treatment Program
Neonatal Abstinence Syndrome (NAS) is a complex condition that occurs when a mother uses drugs, such as opioids, during pregnancy. The drugs pass through the placenta to the baby’s circulatory system resulting in drug dependence at birth.
When infants are born with drug dependence, they are at high risk for feeding and developmental issues as well as problems with learning when they reach school age. They also suffer from common symptoms of withdrawal, such as body shakes or seizures, fussiness, poor feeding, slow weight gain, hyperactivity, vomiting and more.
Good Shepherd Pediatrics NAS Treatment Program offers help to alleviate the symptoms of withdrawal and also to facilitate positive caregiver-infant interaction and bonding. The therapeutic program takes place in a developmentally appropriate, low-stimulation environment and is led by a pediatrician and a physical medicine and rehabilitation physician. Read more about the treatment team.
Inpatient Services Include:
- Comprehensive evaluation upon admission
- Care by a multi-disciplinary team of professionals, including physicians, pediatric specialty nurses, pediatric dieticians, speech, physical and occupational therapists and behavioral counselors
- Feeding therapy with staff members who have advanced training and expertise in feeding techniques and strategies
- Medication management and weaning
- Interventions to improve autoregulation and sleep-wake cycles
- Weight and growth tracking
- Hands-on caregiver education and training
- Alleviate signs and symptoms of withdrawal
- Maintain optimal nutritional status
- Provide developmentally supportive environment
- Reduce irritability and promote self-calming skills
- Facilitate positive caregiver-infant interaction and bonding
- Provide ongoing caregiver education and support until symptoms resolve
- Provide discharge planning, appropriate referrals and follow-up care
Good Shepherd Rehabilitation Hospital Pediatric Unit
2855 Schoenersville Road
Bethlehem, PA 18017